{"id":"NCT00468728","sponsor":"Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","briefTitle":"PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)","officialTitle":"A Double-Blind Study to Compare the Safety and Efficacy of PAR-101 to Vancomycin in Subjects With Clostridium Difficile-Associated Diarrhea (CDAD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-10-04","primaryCompletion":"2009-12-11","completion":"2009-12-11","firstPosted":"2007-05-03","resultsPosted":"2011-07-29","lastUpdate":"2017-04-21"},"enrollment":535,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Clostridium Infections","Diarrhea"],"interventions":[{"type":"DRUG","name":"PAR-101/OPT-80","otherNames":[]},{"type":"DRUG","name":"Vancomycin","otherNames":[]}],"arms":[{"label":"1","type":"ACTIVE_COMPARATOR"},{"label":"2","type":"EXPERIMENTAL"}],"summary":"This is a comparative study to investigate the safety and efficacy of PAR-101/OPT-80 (fidaxomicin) versus vancomycin in subjects with Clostridium difficile-associated diarrhea (CDAD).","primaryOutcome":{"measure":"Cure Rate at End of Therapy","timeFrame":"Study day 10 (+/- 2 days)","effectByArm":[{"arm":"Vancomycin","deltaMin":86.7,"sd":null},{"arm":"PAR-101/OPT-80","deltaMin":87.7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":116,"countries":["United States","Belgium","Canada","France","Germany","Italy","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["22321770","24599770","23715579","22752865","22752857"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":58,"n":260},"commonTop":["NAUSEA","VOMITING","ABDOMINAL PAIN","HYPOKALAEMIA","HEADACHE"]}}